{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:55:37Z","timestamp":1792032937363,"version":"4.4.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"14","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170200"],"award-info":[{"award-number":["82170200"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82350101"],"award-info":[{"award-number":["82350101"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270216"],"award-info":[{"award-number":["82270216"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170201"],"award-info":[{"award-number":["82170201"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470204"],"award-info":[{"award-number":["82470204"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82400250"],"award-info":[{"award-number":["82400250"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the New Quality Clinical Specialty Program of High-end Medical Disciplinary Construction in Shanghai Pudong New Area"},{"name":"the Natural Science Foundation of Shanghai"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,4,18]]},"DOI":"10.1038\/s41388-026-03706-y","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T07:12:21Z","timestamp":1773385941000},"page":"1247-1259","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["METTL16 enhances proteasome inhibitor resistance in multiple myeloma by inhibiting eIF2\u03b1-PERK interaction and promoting PSMB5 translation"],"prefix":"10.1038","volume":"45","author":[{"given":"Guanli","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejie","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qilin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaolu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shushan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuaikang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gege","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8553-4559","authenticated-orcid":false,"given":"Jumei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"3706_CR1","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99:1802\u201324.","journal-title":"Am J Hematol"},{"key":"3706_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00955-y","volume":"13","author":"D Dutta","year":"2023","unstructured":"Dutta D, Liu J, Wen K, Kurata K, Fulciniti M, Gulla A, et al. BCMA-targeted bortezomib nanotherapy improves therapeutic efficacy, overcomes resistance, and modulates the immune microenvironment in multiple myeloma. Blood Cancer J. 2023;13:184.","journal-title":"Blood Cancer J"},{"key":"3706_CR3","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s41416-020-01191-y","volume":"124","author":"M Ge","year":"2021","unstructured":"Ge M, Qiao Z, Kong Y, Liang H, Sun Y, Lu H, et al. Modulating proteasome inhibitor tolerance in multiple myeloma: an alternative strategy to reverse inevitable resistance. Br J Cancer. 2021;124:770\u20136.","journal-title":"Br J Cancer"},{"key":"3706_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/2050-7771-1-13","volume":"1","author":"S L\u00fc","year":"2013","unstructured":"L\u00fc S, Wang J. The resistance mechanisms of proteasome inhibitor bortezomib. Biomark Res. 2013;1:13.","journal-title":"Biomark Res"},{"key":"3706_CR5","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1158\/1541-7786.MCR-19-1026","volume":"18","author":"CX Shi","year":"2020","unstructured":"Shi CX, Zhu YX, Bruins LA, Bonolo de Campos C, Stewart W, Braggio E, et al. Proteasome subunits differentially control myeloma cell viability and proteasome inhibitor sensitivity. Mol Cancer Res. 2020;18:1453\u201364.","journal-title":"Mol Cancer Res"},{"key":"3706_CR6","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1007\/s11864-024-01273-6","volume":"25","author":"F Li","year":"2024","unstructured":"Li F, Liu J, Fu Y. Acquired bortezomib resistance in multiple myeloma: from mechanisms to strategy. Curr Treat Options Oncol. 2024;25:1354\u201365.","journal-title":"Curr Treat Options Oncol"},{"key":"3706_CR7","doi-asserted-by":"publisher","first-page":"2176.","DOI":"10.3390\/ijms22042176","volume":"22","author":"A Ruszkowska","year":"2021","unstructured":"Ruszkowska A. METTL16, methyltransferase-like protein 16: current insights into structure and function. Int J Mol Sci. 2021;22:2176.","journal-title":"Int J Mol Sci"},{"key":"3706_CR8","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.cell.2017.05.003","volume":"169","author":"KE Pendleton","year":"2017","unstructured":"Pendleton KE, Chen B, Liu K, Hunter OV, Xie Y, Tu BP, et al. The U6 snRNA m(6)A methyltransferase METTL16 regulates SAM synthetase intron retention. Cell. 2017;169:824 \u2013835.e14.","journal-title":"Cell"},{"key":"3706_CR9","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.molcel.2018.08.004","volume":"71","author":"M Mendel","year":"2018","unstructured":"Mendel M, Chen KM, Homolka D, Gos P, Pandey RR, McCarthy AA, et al. Methylation of structured RNA by the m(6)A writer METTL16 is essential for mouse embryonic development. Mol Cell. 2018;71:986\u20131000.e1011.","journal-title":"Mol Cell"},{"key":"3706_CR10","doi-asserted-by":"publisher","first-page":"5157","DOI":"10.1093\/nar\/gkaa227","volume":"48","author":"T Aoyama","year":"2020","unstructured":"Aoyama T, Yamashita S, Tomita K. Mechanistic insights into m6A modification of U6 snRNA by human METTL16. Nucleic Acids Res. 2020;48:5157\u201368.","journal-title":"Nucleic Acids Res"},{"key":"3706_CR11","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41556-021-00835-2","volume":"24","author":"R Su","year":"2022","unstructured":"Su R, Dong L, Li Y, Gao M, He PC, Liu W, et al. METTL16 exerts an m(6)A-independent function to facilitate translation and tumorigenesis. Nat Cell Biol. 2022;24:205\u201316.","journal-title":"Nat Cell Biol"},{"key":"3706_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112150","volume":"42","author":"F Wang","year":"2023","unstructured":"Wang F, Zhang J, Lin X, Yang L, Zhou Q, Mi X, et al. METTL16 promotes translation and lung tumorigenesis by sequestering cytoplasmic eIF4E2. Cell Rep. 2023;42:112150.","journal-title":"Cell Rep"},{"key":"3706_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13045-024-01526-9","volume":"17","author":"M Xue","year":"2024","unstructured":"Xue M, Dong L, Zhang H, Li Y, Qiu K, Zhao Z, et al. METTL16 promotes liver cancer stem cell self-renewal via controlling ribosome biogenesis and mRNA translation. J Hematol Oncol. 2024;17:7.","journal-title":"J Hematol Oncol"},{"key":"3706_CR14","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.stem.2022.12.006","volume":"30","author":"L Han","year":"2023","unstructured":"Han L, Dong L, Leung K, Zhao Z, Li Y, Gao L, et al. METTL16 drives leukemogenesis and leukemia stem cell self-renewal by reprogramming BCAA metabolism. Cell Stem Cell. 2023;30:52\u201368.e13.","journal-title":"Cell Stem Cell"},{"key":"3706_CR15","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13045-024-01599-6","volume":"17","author":"J Wang","year":"2024","unstructured":"Wang J, Xiu M, Wang J, Gao Y, Li Y. METTL16-SENP3-LTF axis confers ferroptosis resistance and facilitates tumorigenesis in hepatocellular carcinoma. J Hematol Oncol. 2024;17:78.","journal-title":"J Hematol Oncol"},{"key":"3706_CR16","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13046-023-02732-y","volume":"42","author":"W Wei","year":"2023","unstructured":"Wei W, Zhang ZY, Shi B, Cai Y, Zhang HS, Sun CL, et al. METTL16 promotes glycolytic metabolism reprogramming and colorectal cancer progression. J Exp Clin Cancer Res. 2023;42:151.","journal-title":"J Exp Clin Cancer Res"},{"key":"3706_CR17","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00018-024-05146-x","volume":"81","author":"Q Li","year":"2024","unstructured":"Li Q, Wang Y, Meng X, Wang W, Duan F, Chen S, et al. METTL16 inhibits papillary thyroid cancer tumorigenicity through m(6)A\/YTHDC2\/SCD1-regulated lipid metabolism. Cell Mol Life Sci. 2024;81:81.","journal-title":"Cell Mol Life Sci"},{"key":"3706_CR18","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.tcb.2020.04.008","volume":"30","author":"S Sonneveld","year":"2020","unstructured":"Sonneveld S, Verhagen BMP, Tanenbaum ME. Heterogeneity in mRNA Translation. Trends Cell Biol. 2020;30:606\u201318.","journal-title":"Trends Cell Biol"},{"key":"3706_CR19","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/j.cell.2013.05.049","volume":"153","author":"P Shah","year":"2013","unstructured":"Shah P, Ding Y, Niemczyk M, Kudla G, Plotkin JB. Rate-limiting steps in yeast protein translation. Cell. 2013;153:1589\u2013601.","journal-title":"Cell"},{"key":"3706_CR20","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41392-020-00444-9","volume":"6","author":"P Song","year":"2021","unstructured":"Song P, Yang F, Jin H, Wang X. The regulation of protein translation and its implications for cancer. Signal Transduct Target Ther. 2021;6:68.","journal-title":"Signal Transduct Target Ther"},{"key":"3706_CR21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12929-023-00924-4","volume":"30","author":"YW Hung","year":"2023","unstructured":"Hung YW, Ouyang C, Ping X, Qi Y, Wang YC, Kung HJ, et al. Extracellular arginine availability modulates eIF2\u03b1 O-GlcNAcylation and heme oxygenase 1 translation for cellular homeostasis. J Biomed Sci. 2023;30:32.","journal-title":"J Biomed Sci"},{"key":"3706_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50910-z","volume":"15","author":"S Xiong","year":"2024","unstructured":"Xiong S, Zhou J, Tan TK, Chung TH, Tan TZ, Toh SH, et al. Super enhancer acquisition drives expression of oncogenic PPP1R15B that regulates protein homeostasis in multiple myeloma. Nat Commun. 2024;15:6810.","journal-title":"Nat Commun"},{"key":"3706_CR23","first-page":"1206","volume":"109","author":"G Chen","year":"2024","unstructured":"Chen G, Gao X, Jia X, Wang Y, Xu L, Yu D, et al. Ribosomal protein S3 mediates drug resistance of proteasome inhibitor: potential therapeutic application in multiple myeloma. Haematologica. 2024;109:1206\u201319.","journal-title":"Haematologica"},{"key":"3706_CR24","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12929-022-00813-2","volume":"29","author":"Y Xie","year":"2022","unstructured":"Xie Y, Wang Y, Xu Z, Lu Y, Song D, Gao L, et al. Preclinical validation and phase I trial of 4-hydroxysalicylanilide, targeting ribonucleotide reductase mediated dNTP synthesis in multiple myeloma. J Biomed Sci. 2022;29:32.","journal-title":"J Biomed Sci"},{"key":"3706_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12929-024-01101-x","volume":"32","author":"X Gao","year":"2025","unstructured":"Gao X, Feng Q, Zhang Q, Zhang Y, Hu C, Zhang L, et al. Targeting enolase 1 reverses bortezomib resistance in multiple myeloma through YWHAZ\/Parkin axis. J Biomed Sci. 2025;32:9.","journal-title":"J Biomed Sci"},{"key":"3706_CR26","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.3324\/haematol.2022.280857","volume":"107","author":"M Engelhardt","year":"2022","unstructured":"Engelhardt M, Waldschmidt JM, W\u00e4sch R. Proteasome inhibition: the dawn of novel therapies in multiple myeloma. Haematologica. 2022;107:1018\u20139.","journal-title":"Haematologica"},{"key":"3706_CR27","first-page":"Cd010816","volume":"4","author":"K Scott","year":"2016","unstructured":"Scott K, Hayden PJ, Will A, Wheatley K, Coyne I. Bortezomib for the treatment of multiple myeloma. Cochrane Database Syst Rev. 2016;4:Cd010816.","journal-title":"Cochrane Database Syst Rev"},{"key":"3706_CR28","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41375-018-0216-8","volume":"33","author":"S Barrio","year":"2019","unstructured":"Barrio S, St\u00fchmer T, Da-Vi\u00e1 M, Barrio-Garcia C, Lehners N, Besse A, et al. Spectrum and functional validation of PSMB5 mutations in multiple myeloma. Leukemia. 2019;33:447\u201356.","journal-title":"Leukemia"},{"key":"3706_CR29","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd4505","volume":"14","author":"M Bhat","year":"2015","unstructured":"Bhat M, Robichaud N, Hulea L, Sonenberg N, Pelletier J, Topisirovic I. Targeting the translation machinery in cancer. Nat Rev Drug Discov. 2015;14:261\u201378.","journal-title":"Nat Rev Drug Discov"},{"key":"3706_CR30","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.cell.2009.01.042","volume":"136","author":"N Sonenberg","year":"2009","unstructured":"Sonenberg N, Hinnebusch AG. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell. 2009;136:731\u201345.","journal-title":"Cell"},{"key":"3706_CR31","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1158\/0008-5472.CAN-08-3858","volume":"69","author":"DM Schewe","year":"2009","unstructured":"Schewe DM, Aguirre-Ghiso JA. Inhibition of eIF2alpha dephosphorylation maximizes bortezomib efficiency and eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy. Cancer Res. 2009;69:1545\u201352.","journal-title":"Cancer Res"},{"key":"3706_CR32","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1007\/s00018-012-1252-6","volume":"70","author":"N Donnelly","year":"2013","unstructured":"Donnelly N, Gorman AM, Gupta S, Samali A. The eIF2\u03b1 kinases: their structures and functions. Cell Mol Life Sci. 2013;70:3493\u2013511.","journal-title":"Cell Mol Life Sci"},{"key":"3706_CR33","doi-asserted-by":"publisher","first-page":"e176136.","DOI":"10.1172\/JCI176136","volume":"134","author":"C Muralidharan","year":"2024","unstructured":"Muralidharan C, Huang F, Enriquez JR, Wang JE, Nelson JB, Nargis T, et al. Inhibition of the eukaryotic initiation factor-2\u00e0 kinase PERK decreases risk of autoimmune diabetes in mice. J Clin Invest. 2024;134:e176136.","journal-title":"J Clin Invest"},{"key":"3706_CR34","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1182\/bloodadvances.2020003820","volume":"6","author":"T Chen","year":"2022","unstructured":"Chen T, Ho M, Briere J, Moscvin M, Czarnecki PG, Anderson KC, et al. Multiple myeloma cells depend on the DDI2\/NRF1-mediated proteasome stress response for survival. Blood Adv. 2022;6:429\u201340.","journal-title":"Blood Adv"},{"key":"3706_CR35","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.semcdb.2023.08.002","volume":"156","author":"R Kandel","year":"2024","unstructured":"Kandel R, Jung J, Neal S. Proteotoxic stress and the ubiquitin proteasome system. Semin Cell Dev Biol. 2024;156:107\u201320.","journal-title":"Semin Cell Dev Biol"},{"key":"3706_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116038","volume":"221","author":"D Zhou","year":"2024","unstructured":"Zhou D, Yin M, Kang B, Yu X, Zeng H, Chen B, et al. CCT020312 exerts anti-prostate cancer effect by inducing G1 cell cycle arrest, apoptosis and autophagy through activation of PERK\/eIF2\u03b1\/ATF4\/CHOP signaling. Biochem Pharmacol. 2024;221:116038.","journal-title":"Biochem Pharmacol"},{"key":"3706_CR37","doi-asserted-by":"publisher","first-page":"eaal2668.","DOI":"10.1126\/scitranslmed.aal2668","volume":"9","author":"S Manier","year":"2017","unstructured":"Manier S, Huynh D, Shen YJ, Zhou J, Yusufzai T, Salem KZ, et al. Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma. Sci Transl Med. 2017;9:eaal2668.","journal-title":"Sci Transl Med"},{"key":"3706_CR38","doi-asserted-by":"publisher","first-page":"29.","DOI":"10.3390\/cells13010029","volume":"13","author":"D Spano","year":"2023","unstructured":"Spano D, Catara G. Targeting the ubiquitin-proteasome system and recent advances in cancer therapy. Cells. 2023;13:29.","journal-title":"Cells"},{"key":"3706_CR39","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41580-018-0040-z","volume":"19","author":"A Rousseau","year":"2018","unstructured":"Rousseau A, Bertolotti A. Regulation of proteasome assembly and activity in health and disease. Nat Rev Mol Cell Biol. 2018;19:697\u2013712.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3706_CR40","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s10555-017-9707-8","volume":"36","author":"S Gandolfi","year":"2017","unstructured":"Gandolfi S, Laubach JP, Hideshima T, Chauhan D, Anderson KC, Richardson PG. The proteasome and proteasome inhibitors in multiple myeloma. Cancer Metastasis Rev. 2017;36:561\u201384.","journal-title":"Cancer Metastasis Rev"},{"key":"3706_CR41","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41580-024-00778-0","volume":"26","author":"C Arkinson","year":"2025","unstructured":"Arkinson C, Dong KC, Gee CL, Martin A. Mechanisms and regulation of substrate degradation by the 26S proteasome. Nat Rev Mol Cell Biol. 2025;26:104\u201322.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3706_CR42","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2007-08-104950","volume":"112","author":"R Oerlemans","year":"2008","unstructured":"Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR, et al. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood. 2008;112:2489\u201399.","journal-title":"Blood"},{"key":"3706_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56867-x","volume":"16","author":"Y Wang","year":"2025","unstructured":"Wang Y, Wang Y, Iriki T, Hashimoto E, Inami M, Hashimoto S, et al. The DYT6 dystonia causative protein THAP1 is responsible for proteasome activity via PSMB5 transcriptional regulation. Nat Commun. 2025;16:1600.","journal-title":"Nat Commun"},{"key":"3706_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56782-1","volume":"16","author":"DE Ramage","year":"2025","unstructured":"Ramage DE, Grant DW, Timms RT. Loss-of-function mutations in the dystonia gene THAP1 impair proteasome function by inhibiting PSMB5 expression. Nat Commun. 2025;16:1511.","journal-title":"Nat Commun"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03706-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03706-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03706-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T22:02:07Z","timestamp":1774821727000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03706-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":44,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2026,4,18]]}},"alternative-id":["3706"],"URL":"https:\/\/doi.org\/10.1038\/s41388-026-03706-y","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"23 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Bone marrow samples were obtained from MM patients and healthy donors after informed consent was obtained from all participants. The study protocol was reviewed and approved by the Ethics Committee of Shanghai East Hospital (Approval ID: 2024YS-254). All animal experiments were conducted in accordance with institutional and national guidelines for laboratory animal care and use and were approved by the Shanghai East Hospital (Approval ID: TJBB00223101).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}